The Consortium aims to accelerate the development of biomarker-based technologies
Claudio Carini, a member of Oxford BioDynamics’ Scientific Advisory Panel, has been invited to join the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium as a member of the Cancer, Inflammation and Immunity, and Neuroscience Steering Committees.
Oxford BioDynamics is a biotechnology company focused on the discovery and development of novel epigenetic biomarkers.
The Biomarkers Consortium is a public-private biomedical research partnership managed by the FNIH that endeavours to discover, develop and seek regulatory approval for biological markers, known as biomarkers, to support new drug development, precision medicine and medical diagnostics.
The Consortium aims to accelerate the development of biomarker-based technologies, medicines, and therapies for the prevention, early detection, diagnosis, and treatment of disease.
The Steering Committees are responsible for identifying and moving forward promising pre-competitive biomarkers projects for implementation by The Biomarkers Consortium, as well as overseeing each individual project under its purview.
The members of each Steering Committee represent a variety of sectors, including academia, government, industry and not-for-profit/advocacy organisations.
Carini has prior experience as a member of the FNIH Biomarkers Consortium Steering Committees, as well as having consulted and sat on many other distinguished international advisory boards and committees including: the Medical Research Council (UK), Innovative Medicine Initiative (IMI-EU) and the PML Consortium.